Oklahoma, a state ravaged by the opioid epidemic and a number of addiction crises that followed, just secured a $250 million settlement with pharma distributors McKesson, Cardinal, and AmerisourceBergen for the role those companies played in Oklahoma’s addiction epidemic. Hopefully, Oklahoma will use the settlement to fund desperately needed treatment programs for struggling addicts.
The last few years have seen hundreds of court cases levied against pharmaceutical companies for their role in fueling the opioid epidemic. One recent development came in the form of an unfortunate loss for plaintiffs, when the Oklahoma Supreme Court ruled in favor of Johnson & Johnson.
In the last year, several pharmaceutical lawsuits have come to the forefront of our attention. We can thank the media for that. But in this case, it’s a good thing that these lawsuits have been reported on so extensively. We’re speaking of course of the state and federal lawsuits against pharma companies for the hand that such organizations played in the creation of the opiate epidemic.
According to the National Institute on Drug Abuse, more than 130 people die from overdoses on opioid drugs every day. Such opioids include pharmaceutical pain relievers, heroin, fentanyl, and synthetic hybrid combinations of different opioid drugs.